Clinical Trial Update: A Study to Access Activity and Safety With SAR445399 Compared With Placebo in Participants Aged 18 to 80 Years of Age With Non-Cystic Fibrosis Bronchiectasis [Phase 2]

View source ↗

Summary

Phase 2 trial to assess activity and safety of SAR445399 versus placebo in adults with non-cystic fibrosis bronchiectasis; status is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-cystic Fibrosis Bronchiectasis

Drugs mentioned

• SAR445399

Snippet

Sponsor: Sanofi | Conditions: Non-cystic Fibrosis Bronchiectasis | Phase 2 | Status: NOT_YET_RECRUITING